Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) (Aurora)

8. července 2026 aktualizováno: Lu Huaiwu, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

A Prospective, Open-label, Randomized, Controlled, Non-inferiority Phase II Study Comparing HAL-PDT With Deferred Surgery Versus Immediate Surgery in Subjects With High-grade Squamous Intraepithelial Lesions (HSIL)

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention. This Phase II study aims to comprehensively evaluate the efficacy, safety, and impact on quality of life of hexaminolevulinate photodynamic therapy (HAL-PDT) with deferred surgery compared to immediate surgical treatment in subjects with HSIL.

This is a prospective, open-label, randomized, controlled, non-inferiority trial. A total of 230 subjects are planned to be enrolled, with 115 subjects allocated to each treatment group (HAL-PDT with Deferred Surgery or Immediate Surgery ).

The primary endpoint is the pathological regression rate at 12 months, defined as histological findings of normal tissue or low-grade squamous intraepithelial lesions (LSIL) via colposcopy-directed biopsy. Key secondary endpoints include Human Papillomavirus (HPV) clearance rates at 6 and 12 months, pathological regression rate at 6 months, quality of life assessed by the EORTC QLQ-CX24 questionnaire, safety profiles (incidence, severity, and duration of AEs and SAEs, as well as their relationship to the study treatments), and the proportion of subjects developing cervical cancer within 12 months.

Přehled studie

Detailní popis

High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are well-established precursors to invasive cervical cancer. Immediate excisional procedures such as loop electrosurgical excision procedure (LEEP) or cold knife conization remain the standard of care; however, they are associated with significant long-term morbidities, including cervical stenosis, cervical incompetence, and adverse obstetric outcomes in women of childbearing age. Hexaminolevulinate photodynamic therapy (HAL-PDT) is a non-invasive, tissue-preserving modality that offers a potential alternative.

This Phase II trial is designed to test the hypothesis that HAL-PDT (HAL-PDT Q2W×6 ) with deferred surgery achieves a 12-month pathological regression rate non-inferior to that of immediate surgery, while providing a favorable safety and quality-of-life profile.

A total of 230 subjects are planned for enrollment, with 115 allocated to each treatment arm. The primary efficacy analysis will be performed on both the Intention-to-Treat (ITT) and Per-Protocol (PP) populations to test the non-inferiority margin, which is pre-specified based on clinically acceptable thresholds. Safety analyses will be conducted on the Safety Set (SS).

Typ studie

Intervenční

Zápis (Odhadovaný)

230

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Fujian
      • Fuzhou, Fujian, Čína, 350001
        • Fujian Medical University Union Hospital
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 0591-83357896
          • E-mail: fjxhe_irb@163.com
        • Vrchní vyšetřovatel:
          • Dezhao Chen, MD, PhD
      • Fuzhou, Fujian, Čína, 350005
        • The First Affiliated Hospital of Fujian Medical University
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 0591-87982001
          • E-mail: fdyy_irb@163.com
        • Vrchní vyšetřovatel:
          • Lihong Chen, MD, PhD
      • Xiamen, Fujian, Čína, 361001
        • Xiamen Maternity and Child Healthcare Hospital
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 0592-2662920
          • E-mail: xmfyllwyh@163.com
        • Vrchní vyšetřovatel:
          • Qing Li, MD, PHD
      • Xiamen, Fujian, Čína, 361003
        • he First Affiliated Hospital of Xiamen University
        • Kontakt:
          • Jiajie Lin
          • Telefonní číslo: +86-0592-2137569
          • E-mail: xdfyec@163.com
        • Vrchní vyšetřovatel:
          • Qionghua Chen, MD, PHD
    • Guangdong
      • Foshan, Guangdong, Čína, 528000
        • The First People's Hospital of Foshan
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Lijiang Xu, MD, PHD
      • Foshan, Guangdong, Čína, 528300
        • Foshan Shunde Maternal and Child Health Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Jinzhi Huang, MD, PHD
      • Guangzhou, Guangdong, Čína, 510280
        • Zhujiang Hospital, Southern Medical University
        • Kontakt:
          • Ethics Office Administrator
          • Telefonní číslo: +86-020-62783372
          • E-mail: zjyygcp@163.com
        • Vrchní vyšetřovatel:
          • Xuefeng Wang, MD, PhD
      • Guangzhou, Guangdong, Čína, 510010
        • Guangdong Women and Children Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Xiaoli Sun, MD, PHD
      • Guangzhou, Guangdong, Čína, 510095
        • The Affiliated Cancer Hospital of Guangzhou Medical University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Bin Wen, MD, PhD
      • Guangzhou, Guangdong, Čína, 510120
        • Guangdong ProvincialHospital of Chinese Medicine
        • Kontakt:
          • Administrator Ethics Committee
          • Telefonní číslo: 020-81887233-35943
          • E-mail: Ilbgs@gzucm.edu.cn
        • Vrchní vyšetřovatel:
          • Jing Xiao, MD, PhD
      • Guangzhou, Guangdong, Čína, 510180
        • Guangzhou First People's Hospital (The Second Affiliated Hospital of South China University of Technology)
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 020-81045412
          • E-mail: MEC_GZSY@126.com
        • Vrchní vyšetřovatel:
          • Yan Kuang, MD, PhD
      • Guangzhou, Guangdong, Čína, 510317
        • Guangdong Second Provincial GeneralHospital (Guangdong Provincial Emergency Hospital)
        • Kontakt:
          • Administrator Clinical Research Office
          • Telefonní číslo: +86-20-89168338
          • E-mail: gdech_irb@163.com
        • Vrchní vyšetřovatel:
          • Xiafei Fu, MD, PhD
      • Guangzhou, Guangdong, Čína, 510405
        • The First AffiliatedHospital, Guangzhou University ofTraditional Chinese Medicine
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: +86-20-36588667
          • E-mail: gztcmlunli@163.com
        • Vrchní vyšetřovatel:
          • Sijin Li, MD, PhD
      • Guangzhou, Guangdong, Čína, 510623
        • Guangzhou Women and Children's Medical Center (The Affiliated Women and Children's Medical Center of Guangzhou Medical University)
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 020-81886332
          • E-mail: gzwc_irb@163.com
        • Vrchní vyšetřovatel:
          • Kun Shi, MD, PhD
      • Guangzhou, Guangdong, Čína, 511400
        • Panyu Central Hospital Affiliated to Guangzhou Medical University
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 020-34858888
          • E-mail: pyzxylunli@163.com
        • Vrchní vyšetřovatel:
          • Xiang Yang, MD, PhD
      • Shenzhen, Guangdong, Čína, 518036
        • Peking University Shenzhen Hospital
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 0755-83923333
          • E-mail: pkuszh_irb@163.com
        • Vrchní vyšetřovatel:
          • Zhihong Liu, MD, PhD
      • Shenzhen, Guangdong, Čína, 518031
        • Shenzhen Maternity and Child Health Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Ping Jin, MD, PHD
      • Zhongshan, Guangdong, Čína, 510080
        • The First Affiliated Hospital, Sun Yat-sen University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Mian He, MD, PHD
        • Vrchní vyšetřovatel:
          • Junxiu Liu, MD, PHD
    • Guangxi
      • Nanning, Guangxi, Čína, 530021
        • The First Affiliated Hospital of Guangxi Medical University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Jiangtao Fan, MD, PhD
      • Nanning, Guangxi, Čína, 530000
        • Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Chunqiu Xiong, MD, PHD
    • Guangzhou
      • Dongguan, Guangzhou, Čína, 523000
        • Dongguan Maternal and Child Health Care Hosptial
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Ping Zhou, MD, PHD
    • Henan
      • Zhengzhou, Henan, Čína, 450052
        • The First Affiliated Hospital of Zhengzhou University
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 0371-66278510
          • E-mail: zdyyllwy@163.com
        • Vrchní vyšetřovatel:
          • Liping Han, MD, PhD
    • Jiangsu
      • Nanjing, Jiangsu, Čína, 210029
        • The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial People's Hospital)
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 025-68136360
          • E-mail: jsphkj@163.com
        • Vrchní vyšetřovatel:
          • Xiaoling Ma, MD, PhD
    • Jinlin
      • Changchun, Jinlin, Čína
        • The First Hospital of Jilin University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Songling Zhang, MD, PHD
    • Liaoning
      • Shenyang, Liaoning, Čína, 110016
        • The General Hospital of Northern Theater Command of the Chinese People's Liberation Army
        • Kontakt:
          • Ethics Committee Administrator
          • Telefonní číslo: 024-28851114
          • E-mail: btzzyy_irb@163.com
        • Vrchní vyšetřovatel:
          • Lipeng Pei, MD, PhD
    • Shanxi
      • Taiyuan, Shanxi, Čína, 030000
        • Shanxi Provincial People's Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yuping Suo, MD, PHD
    • Sichuan
      • Chengdu, Sichuan, Čína, 610041
        • The West China Second University Hospital of Sichuan University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yuedong He, MD, PHD
    • Zhejiang
      • Hangzhou, Zhejiang, Čína, 310022
        • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Yichen Wang, MD, PhD

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dítě
  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Voluntarily participate in this clinical study, fully understand the study content, procedures, and potential adverse reactions, and be able to sign the written informed consent form.
  • Able to complete the study in accordance with the study protocol.
  • Subject age ≥18 years.
  • Presence of High-Grade Squamous Intraepithelial Lesion (HSIL) (CIN2 P16 positive/CIN3), specifically: HSIL with histopathological diagnosis of grade II/III (CIN2 P16 positive/CIN3) within 3 months prior to the first treatment.
  • Adequate colposcopy, including: (a) Complete visibility of the cervical transformation zone, including the squamocolumnar junction; (b) Complete visibility of lesion margins.
  • The investigator determines that non-surgical treatment is acceptable for the participant.
  • The investigator determines that the cervical size is suitable for placement of the HAL-PDT device.
  • Meets the following conditions: Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result prior to the start of treatment. No plan for pregnancy during the study period; no sexual activity or use of effective and reliable contraception from the end of the last menstrual period to the start of the study, and agreement to use condoms for barrier contraception during the study period. WOCBP is defined as a female who has experienced menarche, has not undergone hysterectomy or bilateral oophorectomy, and has not reached natural menopause (i.e., no menstruation at all for the past 24 consecutive months).

Exclusion Criteria:

  • Cervical adenocarcinoma in situ or other glandular lesions, invasive cervical cancer, or suspected malignant lesions.
  • CIN2 with P16 negative.
  • Lesions extending to the vaginal wall, cervical canal, or vaginal fornix, or lesions located on the vulva.
  • Prior physical or surgical treatment to the cervix resulting in incomplete cervical structure (e.g., cold knife conization), or receipt of physical or surgical therapy for CIN2 or CIN3 after the current histopathological diagnosis.
  • The first study treatment day falls within 7 half-lives of the last antiviral medication.
  • Severe pelvic inflammatory disease, severe cervicitis, or other severe gynecological infectious diseases found on colposcopic or clinical examination.
  • Investigator judges that vaginal bleeding during treatment may affect treatment outcomes.
  • Receipt of any inactivated vaccine within 2 weeks prior to the first treatment, or any live vaccine within 4 weeks prior to the first treatment.
  • Previous severe cardiovascular, cerebrovascular, neurological, psychiatric, endocrine, or hematopoietic disease that has not been cured; known severely compromised immune function, or need for long-term use of corticosteroids or immunosuppressants; history of malignancy within 5 years.
  • History of clinically significant immunosuppression or confirmed autoimmune disease; or primary immunodeficiency.
  • Known or newly identified active sexually transmitted diseases (STDs), including but not limited to HIV, syphilis, genital herpes, unless adequately treated and tested negative before study treatment.
  • Presence of a cardiac pacemaker.
  • Suspected or known porphyria, or known allergy to the study drug, its chemically similar compounds, or photosensitizers.
  • Allergy to silicone.
  • Pregnant or breastfeeding women.
  • Delivery or miscarriage within 6 weeks prior to enrollment.
  • Participation in any other clinical trial within 30 days prior to study treatment.
  • Poor compliance or judged by the investigator to be unsuitable for participation in this clinical study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Hexaminolevulinate Photodynamic Therapy (HAL-PDT) with Deferred Surgery
Subjects receive Hexaminolevulinate Photodynamic Therapy (HAL-PDT) once every 2 weeks (Q2W) for a total of 6 treatment sessions. At 6 months after the first treatment, participants undergo colposcopy-directed cervical biopsy and HPV testing to assess treatment response. Those who achieve pathological remission (normal or LSIL) enter follow-up without surgery. Those who do not achieve remission (persistent HSIL or disease progression) receive standard surgical treatment (LEEP or CKC) within 4 weeks of the 6-month assessment.
HAL-PDT is a drug-device combination product. The drug is hexaminolevulinate hydrochloride (HAL) 5% ointment. The device is a single-use cervical light delivery device (CL7) with integrated red LEDs. The ointment is applied into the device cup, placed against the cervix for 5 hours of drug absorption, then automatically delivers 125 J/cm² photodynamic therapy for 4 hours and 36 minutes. Total in-situ time is 11-24 hours. Patients remove the device themselves. Treatment regimen: one session every 2 weeks for a total of 6 sessions (Q2W × 6).
Aktivní komparátor: Immediate Surgery
Participants with histologically confirmed HSIL (CIN2 P16 positive/CIN3) receive standard surgical treatment (LEEP or CKC) per routine clinical practice. Follow-up assessments include HPV testing and colposcopy-directed cervical biopsy at 6 months and 12 months post-surgery to evaluate pathological remission and HPV clearance rates. Safety monitoring is conducted from signing of informed consent through the end of study.
Subjects undergo immediate surgical excision of the cervical lesion via either Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), as determined by the investigator based on the subject's individual lesion characteristics, size, and clinical presentation, following standard institutional surgical protocols.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Histopathological regression rate at 12 months
Časové okno: 12 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 12 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL)
12 months after the first treatment

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Pathological remission rate at 6 months
Časové okno: 6 months after the first treatment
Proportion of participants with pathological remission on colposcopy-directed cervical biopsy at 6 months after the first treatment. Pathological remission is defined as histopathological finding of normal tissue or low-grade squamous intraepithelial lesion (LSIL).
6 months after the first treatment
HPV baseline clearance rate at 12 months
Časové okno: 12 months after the first treatment
Proportion of participants with clearance of baseline high-risk HPV subtypes at 12 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
12 months after the first treatment
Incidence of cervical cancer at 12 months
Časové okno: 12 months after the first treatment
Proportion of participants with histologically confirmed cervical cancer (any stage) diagnosed within 12 months after the first treatment.
12 months after the first treatment
Human Papillomavirus (HPV) baseline clearance rate at 6 months
Časové okno: 6 months after the first treatment
Proportion of participants with clearance of baseline high-risk Human Papillomavirus (HPV) subtypes at 6 months after the first treatment. HPV clearance is defined as undetectable of the same high-risk HPV subtype(s) that were present at baseline.
6 months after the first treatment
Quality of life assessed by EORTC QLQ-CX24
Časové okno: 12 months after the first treatment
Quality of life assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Cervical Cancer Module (EORTC QLQ-CX24). Scores for each domain are linearly transformed to a 0-100 scale. For global health status and functional domains, a higher score indicates a better outcome (better quality of life/function). For symptom scales, a higher score indicates a worse outcome (more severe symptoms).
12 months after the first treatment
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Časové okno: From informed consent through 12 months after the first treatment
Incidence, type, severity (mild, moderate, severe), duration, and relatedness to photodynamic therapy and/or surgical treatment of adverse events (AEs) and serious adverse events (SAEs) occurring from signing of informed consent through the end of study follow-up.
From informed consent through 12 months after the first treatment

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. července 2026

Primární dokončení (Odhadovaný)

16. června 2029

Dokončení studie (Odhadovaný)

16. června 2029

Termíny zápisu do studia

První předloženo

21. června 2026

První předloženo, které splnilo kritéria kontroly kvality

21. června 2026

První zveřejněno (Aktuální)

25. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

9. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

8. července 2026

Naposledy ověřeno

1. července 2026

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit